Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisEXEL -1.49%88 10-Year RORE % is 24.45 as of Jun. 2026. GuruFocus rates EXEL with a GF Score™ of 88/100 and a GF Value™ of $45.73 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 619 Biotechnology companies, Exelixis ranks better than 90.47% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Exelixis's 10-Year RORE % for the quarter that ended in Jun. 2026 was 24.45%.
The industry rank for Exelixis's 10-Year RORE % or its related term are showing as below:
EXEL's 10-Year RORE % is ranked better than 90.47% of 619
companies
in the Biotechnology industry
Industry Median: -7.09
vs EXEL: 24.45
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Exelixis 10-Year RORE % Related Terms
Exelixis 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Exelixis's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EXEL vs MDGL, AXSM, ARWR: 10-Year RORE % Comparison
For the Biotechnology subindustry, Exelixis's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis 10-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Exelixis's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 10-year before.
Exelixis (EXEL) has a 10-Year RORE % of 24.45 as of Jun. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Exelixis and its competitors. According to the industry distribution chart, Exelixis ranks #59 out of 619 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Exelixis' 10-Year RORE % too high?
Exelixis' current 10-Year RORE % is 24.45. Based on the distribution chart, Exelixis ranks #59 out of 619 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Exelixis has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' 10-Year RORE % compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #59 out of 619 companies for 10-Year RORE %. This places Exelixis in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Exelixis and its competitors. Exelixis's current 10-Year RORE % is 24.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $45.73, compared to a current price of $53.59 — trading 17.2% above its estimated fair value. The current 10-Year RORE % is 24.45. Exelixis' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Exelixis (EXEL), the current 10-Year RORE % is 24.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (EXEL) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of $53.59 is trading 17.2% above its estimated GF Value™ of $45.73.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for EXEL:
10-Year RORE %: 24.45
GF Value™: $45.73 vs. price of $53.59 (17.2% above fair value)
No single metric tells the full story. See the EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
88GF Score
Get the complete analysis for EXEL
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXEL has been successfully added to your 
